In addition to the endeavors to translate HIF-1α antisense oligonucleotides into cancer therapy [34,35,36], several approved chemotherapeutics such as camptothecins, rapamycin analogs, and anthracyclines have been tested clinically for their indirect HIF-1α inhibitory action in various cancers [37]. This evidence concerns the gene HIF1A and cancer.